19 years ago, Bayer Pharmaceuticals introduced the first broad spectrum oral fluoroquinolone, Ciprofloxacin (Cipro®, Ciproxin®). The intravenous formulation of Cipro was introduced in 1991. Cipro is available in more than 100 countries and has been approved for the treatment of 14 types of infections, especially urinary tract infections (UTIs) such as acute uncomplicated cystitis, pyelonephritis, and chronic bacterial prostatitis.
Cipro is considered the "gold standard" therapy for many types of Gram Negative infections, including Pseudomonas aeruginosa, and has maintained a high level of activity against Escherichia coli compared to other agents used for UTIs.
Cipro's 19 year history includes:
- Extensively studied and documented in over 37,000 publications
- More than 100,000 patients enrolled in double blind trials around the world
- Prescribed for more than 340 million patients worldwide
- Extensive and unprecedented safety profile
Your doctor or healthcare provider is the single best source of information regarding you and your health. Please consult your doctor if you have any questions about your health or medication.
Consumers outside the United States please visit Infections.bayer.com for more information on the treatment of infections:
